Tom Powles: Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions
Tom Powles shared a post on X, about recent paper published in ESMO Open:
Authors: Andrea Apolo, Joaquim Bellmunt, Lisa Cordes, Shilpa Gupta, Thomas Powles, Jonathan Rosenberg, Michiel van der Heijden.
”Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions? Sometimes, but clinical judgement is more important than predefined criteria.”
Source: Tom Powles/X
Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre. With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals. His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023